TG Therapeutics Shares Are Trading Higher After the Company Announced It Updated Its Data Presentations to Include New Five-year Data From the ULTIMATE I & II Phase 3 Trials Evaluating Briumvi (Ublituximab-xiiy) at the 2024 European Committee for...

tg therapeutics股價上漲，公司宣佈更新數據報告，包括在2024年歐洲腫瘤學委員會大會上公佈新的五年ULTIMATE I＆II第3期試驗評估Briumvi（Ublituximab-xiiy）的數據。

Benzinga · 09/18 21:13

TG Therapeutics Shares Are Trading Higher After the Company Announced It Updated Its Data Presentations to Include New Five-year Data From the ULTIMATE I & II Phase 3 Trials Evaluating Briumvi (Ublituximab-xiiy) at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting.

tg therapeutics股價上漲，因公司宣佈更新數據展示，包括來自2024年歐洲多發性硬化症年會ULTIMATE I＆II第3期試驗評估Briumvi（Ublituximab-xiiy）的新五年數據。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。